Breckenridge Pharmaceutical, Inc. recalls
5 recalls.
- Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported June 17, 2026 · CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported June 17, 2026 · CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - Duloxetine Delayed-Release Capsules USP recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported May 13, 2026 · CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit - Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported December 10, 2025 · CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit - Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported December 10, 2025 · CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit